Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 25, 2026, Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $105 from $95 and maintained an Outperform rating following quarterly results. Management also provided first-time FY26 net product sales guidance of $670M–$700M for XDEMVY, representing a year-over-year increase of $230M driven by new patient demand, broad payer coverage, and effective direct-to-consumer efforts. The analyst said the outlook puts XDEMVY on track to achieve more than $2B in peak U.S. sales.

Also on February 25, 2026, Guggenheim raised its price target on Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $90 from $87 and reiterated a Buy rating after the company reported what the firm described as “strong” 2025 results. The analyst noted that with 2026 sales guidance of $670M–$700M and only a small portion of the estimated 25M patient Demodex blepharitis market penetrated, the company appears “well-positioned for sustained growth.”

On February 23, 2026, Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) reported Q4 EPS of (20c), compared with consensus estimates of (13c). The company reported Q4 revenue of $151.67M, above the $144.56M consensus estimate. CEO and Chairman Bobak Azamian said XDEMVY has driven “a fundamental shift in eye care,” noting that the company has built broad access and established a growing franchise within two years of launch. Azamian added that the product validates the company’s model of integrating science, commercial execution, and strategic investment, and that the company plans to apply the same framework across its pipeline in ocular rosacea and Lyme disease prevention.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for eye care in the United States.

While we acknowledge the potential of TARS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.